File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study

TitleTreatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study
Authors
KeywordsALL
Children
Chinese
Issue Date2003
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 2003, v. 21 n. 1, p. 1-9 How to Cite?
AbstractA population-based multicentre study for childhood acute lymphoblastic leukemia (ALL) was conducted in Hong Kong from 1993 to 1997. One hundred and forty-five newly diagnosed ALL patients were treated by the HKALL 93 protocol. Patients were stratified into three risk groups according to age, presenting white cell count, immunophenotyping and cytogenetic study. The patients received the same induction and early and late intensification at week 5 and week 20. Fifty-eight standard risk (SR) patients received regular intrathecal methotrexate as CNS preventive therapy, while 49 intermediate risk (IR) patients received high dose intravenous methotrexate and regular intrathecal methotrexate. Thirty-eight high risk (HR) patients were treated with prophylactic cranial irradiation and an additional intensification block at week 35. The induction remission rate was 97.2% with 2% induction death. Two patients died during first complete remission. Relapse occurred in 20.7, 42.9 and 42.1% of SR, IR and HR patients respectively. By multivariate logistic regression, age ≥ 10 years and white cell count ≥ 100 × 109/1 were the two significant variables accounting for mortality. The 5-year overall and event-free survival of the whole group was 81.3 and 62.6% respectively. According to risk groups, the event-free survival was 79, 49 and 61% for SR, IR and HR patients respectively, while the overall survival was 96, 73 and 68% for SR, IR and HR patients respectively. In conclusion, the treatment protocol had low treatment-related mortality but was associated with a rather high relapse rate, especially in IR patients. Salvage therapy achieved sustained second remission in some patients. More intensive treatment especially a late intensification is required to improve the outcome. Copyright © 2002 John Wiley & Sons, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/80149
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLi, CKen_HK
dc.contributor.authorChik, KWen_HK
dc.contributor.authorChan, GCFen_HK
dc.contributor.authorYuen, HLen_HK
dc.contributor.authorLee, ACWen_HK
dc.contributor.authorLi, CKen_HK
dc.contributor.authorShing, MMKen_HK
dc.contributor.authorHa, SYen_HK
dc.contributor.authorLuk, CWen_HK
dc.contributor.authorLing, SCen_HK
dc.contributor.authorCheung, AYKen_HK
dc.date.accessioned2010-09-06T08:02:58Z-
dc.date.available2010-09-06T08:02:58Z-
dc.date.issued2003en_HK
dc.identifier.citationHematological Oncology, 2003, v. 21 n. 1, p. 1-9en_HK
dc.identifier.issn0278-0232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/80149-
dc.description.abstractA population-based multicentre study for childhood acute lymphoblastic leukemia (ALL) was conducted in Hong Kong from 1993 to 1997. One hundred and forty-five newly diagnosed ALL patients were treated by the HKALL 93 protocol. Patients were stratified into three risk groups according to age, presenting white cell count, immunophenotyping and cytogenetic study. The patients received the same induction and early and late intensification at week 5 and week 20. Fifty-eight standard risk (SR) patients received regular intrathecal methotrexate as CNS preventive therapy, while 49 intermediate risk (IR) patients received high dose intravenous methotrexate and regular intrathecal methotrexate. Thirty-eight high risk (HR) patients were treated with prophylactic cranial irradiation and an additional intensification block at week 35. The induction remission rate was 97.2% with 2% induction death. Two patients died during first complete remission. Relapse occurred in 20.7, 42.9 and 42.1% of SR, IR and HR patients respectively. By multivariate logistic regression, age ≥ 10 years and white cell count ≥ 100 × 109/1 were the two significant variables accounting for mortality. The 5-year overall and event-free survival of the whole group was 81.3 and 62.6% respectively. According to risk groups, the event-free survival was 79, 49 and 61% for SR, IR and HR patients respectively, while the overall survival was 96, 73 and 68% for SR, IR and HR patients respectively. In conclusion, the treatment protocol had low treatment-related mortality but was associated with a rather high relapse rate, especially in IR patients. Salvage therapy achieved sustained second remission in some patients. More intensive treatment especially a late intensification is required to improve the outcome. Copyright © 2002 John Wiley & Sons, Ltd.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_HK
dc.relation.ispartofHematological Oncologyen_HK
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.en_HK
dc.subjectALLen_HK
dc.subjectChildrenen_HK
dc.subjectChineseen_HK
dc.titleTreatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0278-0232&volume=21&spage=1&epage=9&date=2003&atitle=Treatment+of+acute+lymphoblastic+leukemia+in+Hong+Kong+children:+HKALL+93+studyen_HK
dc.identifier.emailChan, GCF:gcfchan@hkucc.hku.hken_HK
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hon.698en_HK
dc.identifier.pmid12605417-
dc.identifier.scopuseid_2-s2.0-0037344068en_HK
dc.identifier.hkuros76311en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037344068&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume21en_HK
dc.identifier.issue1en_HK
dc.identifier.spage1en_HK
dc.identifier.epage9en_HK
dc.identifier.isiWOS:000181693700001-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLi, CK=15122650100en_HK
dc.identifier.scopusauthoridChik, KW=35580472400en_HK
dc.identifier.scopusauthoridChan, GCF=16160154400en_HK
dc.identifier.scopusauthoridYuen, HL=7103253677en_HK
dc.identifier.scopusauthoridLee, ACW=7405631431en_HK
dc.identifier.scopusauthoridLi, CK=19035337000en_HK
dc.identifier.scopusauthoridShing, MMK=7006423846en_HK
dc.identifier.scopusauthoridHa, SY=7202501115en_HK
dc.identifier.scopusauthoridLuk, CW=7005748744en_HK
dc.identifier.scopusauthoridLing, SC=7102701299en_HK
dc.identifier.scopusauthoridCheung, AYK=7401806408en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats